08:16 AM EDT, 06/26/2025 (MT Newswires) -- Alto Neuroscience ( ANRO ) said Thursday it was able to identify a patient selection biomarker in its exploratory phase 2 proof-of-concept trial of ALTO-203 in major depressive disorder patients with elevated levels of anhedonia.

ALTO-203 demonstrated "clear effects on objective measures of attention and wakefulness," in the phase 2 trial, the company said.

The trial, which enrolled 69 patients, was set up to define the pharmacodynamic, pharmacokinetic, safety, and tolerability profile of ALTO-203 across two dose levels compared to placebo in a crossover design, Alto said.

The company said it plans to report additional results from the trial at a future medical meeting and expects to determine the next development steps for the drug following a complete analysis of the data set.